Aclarion Announces Nociscan® Cost-Effectiveness Poster Presented at 45th Annual SMDM Meeting
Aclarion's Nociscan cost-effectiveness study showcased at medical decision making meeting
Positive
Nociscan statistically dominates provocative discography in terms of cost and effectiveness
Nociscan can save the US healthcare system from $283M to $441M annually
10/24/2023 - 08:45 AM
Nociscan cost-effectiveness abstract poster highlights dominance over provocative discography.
The 45th Annual Society for Medical Decision Making (SMDM) Meeting is being held October 22-25, 2023.
Founded in 1979, SMDM promotes scientific and methodological rigor in health care decision research and its application to health policy and clinical care.
Highlighting the importance of the cost savings and improved outcomes associated with Nociscan, SMDM represents the third society meeting, showcasing the Economic Value Analysis of Low back pain (EVAL) study in 2023
BROOMFIELD, CO, Oct. 24, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence algorithms to help physicians identify the location of chronic low back pain, announced today their Nociscan cost-effectiveness poster will be showcased at the 45th Annual Society for Medical Decision Making meeting, October 22-25, 2023. The cost-effectiveness study comparing Nociscan to provocative discography was performed at the Center for Disruptive Musculoskeletal Innovations (CDMI) through a National Science Foundation (NSF) grant and sponsored by Aclarion. The abstract highlights that Nociscan statistically dominates provocative discography (PD) because PD is both more costly and less effective.
"An evidence-based process for accurate identification of a source for low back pain is valuable to improve cost-effectiveness of operative and non-operative management strategies," said Leslie Wilson, PhD, Professor in the Department of Medicine and the Department of Clinical Pharmacy at University of California San Francisco. “The economic model includes a decision-tree comparing Nociscan with PD based on a comprehensive set of peer-reviewed data. The incremental cost-effectiveness ratio (ICER) confirms that Nociscan dominates PD, with a Monte Carlo sensitivity analysis illustrating Nociscan dominates from 40-85% over a wide willingness-to-pay range. In total, Nociscan can save the US healthcare system from $283M to $441M annually.”
Chronic low back pain (cLBP) is a global healthcare problem, with approximately 266 million people worldwide suffering from degenerative spine disease and low back pain. Conventional imaging and diagnostics provide valuable structural information but struggle to identify the source of the pathogenic pain. Low surgical success rates (41-57% )1,2 are common especially for patients suffering from Discogenic Chronic Low Back Pain (DCLP).
“We are pleased with the compounding interest in the Nociscan cost-effectiveness research,” said Ryan Bond, Chief Strategy Officer at Aclarion. “SMDM serves a leading role at the nexus of policy, health economics, and clinical decision making, three areas of interest to Aclarion and our physician customers. Moreover, SMDM joins other leading societies – ISASS for spine surgery and ASPN for pain and neuroscience – who showcased similar Nociscan cost-effectiveness research at their annual meetings earlier this year. Combined with our published clinical evidence, Aclarion is proud of this important evolving research and the clear results – Nociscan shows clinical benefit vs PD while reducing cost-of-care.”
In June 2023, a Nociscan cost-effectiveness abstract was presented by Dr. Wilson at the International Society for the Advancement of Spine Surgery (ISASS) annual meeting. In July 2023, a Nociscan cost-effectiveness poster was presented at the American Society for Pain & Neuroscience (ASPN) annual meeting.
Wei J, Song Y, et al. Comparison of artificial total disc replacement versus fusion for lumbar disc disease: a meta-anaylsis of randomized controlled trials. Int Orthop. 2013; 37(7):1315-1325 Ibrahim T, Tieyjeh IM, et al. Surgical versus nonsurgical treatment of chronic low back pain: a meta-analysis of randomized trials. Int Orthop. 2008; 32(1):107-113 About Aclarion, Inc.
Aclarion is a healthcare technology company that leverages Magnetic Resonance Spectroscopy (“MRS”), proprietary signal processing techniques, biomarkers, and augmented intelligence algorithms to optimize clinical treatments. The Company is first addressing the chronic low back pain market with Nociscan, the first, evidence-supported, SaaS platform to noninvasively help physicians distinguish between painful and nonpainful discs in the lumbar spine. Through a cloud connection, Nociscan receives magnetic resonance spectroscopy (MRS) data from an MRI machine for each lumbar disc being evaluated. In the cloud, proprietary signal processing techniques extract and quantify chemical biomarkers demonstrated to be associated with disc pain. Biomarker data is entered into proprietary algorithms to indicate if a disc may be a source of pain. When used with other diagnostic tools, Nociscan provides critical insights into the location of a patient’s low back pain, giving physicians clarity to optimize treatment strategies. For more information, please visit www.aclarion.com
Forward Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 about the Company's current expectations about future results, performance, prospects and opportunities. Statements that are not historical facts, such as "anticipates," "believes" and "expects" or similar expressions, are forward-looking statements. These forward-looking statements are based on the current plans and expectations of management and are subject to a number of uncertainties and risks that could significantly affect the Company's current plans and expectations, as well as future results of operations and financial condition. These and other risks and uncertainties are discussed more fully in our filings with the Securities and Exchange Commission. Readers are encouraged to review the section titled "Risk Factors" in the Company's Annual Report on Form 10-K for the year ended December 31, 2022, as well as other disclosures contained in the Prospectus and subsequent filings made with the Securities and Exchange Commission. Forward-looking statements contained in this announcement are made as of this date and the Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
Investor Contacts: ksmith@pcgadvisory.com
Media Contacts: jodi@sprigconsulting.com
What is the importance of the Nociscan cost-effectiveness study?
The study highlights that Nociscan is more cost-effective and effective compared to provocative discography.
How much can Nociscan save the US healthcare system?
Nociscan can save the US healthcare system from $283M to $441M annually.
What is the significance of the 45th Annual Society for Medical Decision Making meeting?
The meeting showcases scientific and methodological rigor in health care decision research and its application to health policy and clinical care.
What are the other societies that showcased Nociscan cost-effectiveness research?
ISASS for spine surgery and ASPN for pain and neuroscience showcased similar research at their annual meetings.
What is the global problem related to chronic low back pain?
Approximately 266 million people worldwide suffer from degenerative spine disease and low back pain.
What is Aclarion's perspective on the Nociscan cost-effectiveness research?
Aclarion is pleased with the interest in the research and believes it shows clinical benefit while reducing cost-of-care.
